Harvard Bioscience Inc. has announced a CEO succession plan, with current Board member John Duke set to become President & CEO following the planned retirement of Jim Green, effective July 28, 2025. Jim Green is retiring after over 8 years as Chairman and 6 years as President & CEO. Additionally, Rob Gagnon and Seth Benson have been appointed as new independent Board members. The company anticipates Q2 2025 revenue of $20.4 million and maintains its previously announced gross margin guidance.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.